Loading...
•
Dec 31, 2021
Enanta Pharmaceuticals Q1 2022 Earnings Report
Reported financial results for the fiscal first quarter ended December 31, 2021.
Key Takeaways
Enanta Pharmaceuticals reported a total revenue of $27.6 million for the three months ended December 31, 2021, consisting entirely of royalty revenue. The company's net loss for the quarter was $30.1 million, or a loss of $1.48 per diluted common share. Enanta expects to begin dosing subjects this month with EDP-235, its SARS-CoV-2 3CL protease inhibitor, and completed enrollment in RSVP, a Phase 2b Study of EDP-938 in adults with community-acquired RSV, with topline data expected in the second quarter of 2022.
Expects to begin dosing in a first-in-human study of EDP-235, an oral 3CL protease inhibitor specifically designed for the treatment of COVID-19, this month.
Completed enrollment in RSVP, a Phase 2b Study of EDP-938 in adults with community-acquired Respiratory Syncytial Virus (RSV); expects topline data in the second quarter of 2022.
Plans to initiate a Phase 1 study of EDP-323, an RSV L-Protein Inhibitor, in the second half of 2022.
Royalty revenue for the quarter was $27.6 million.
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Enanta Pharmaceuticals Revenue by Segment
Revenue by Segment
Royalty Revenue
CapyFin.com Forward Guidance
Enanta expects that its current cash, cash equivalents and marketable securities, as well as its continuing royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs for at least the next two years.